Back

Exploring the clinical relevance of TSAT <21% as an iron deficiency indicator in pulmonary arterial hypertension: a comparative analysis with alternative criteria and existing guidelines

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in valvular and pulmonary 4 Pulmonary Hypertension HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nazar Ilchyshyn

Hospital Garcia de Orta, Almada (Portugal)

3 More presentations in this session

Presentation thumbnail
Long-term survival outcomes and baseline hemodynamics in patients with PAH versus CTEPH
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Real-world results of selexipag in treating pulmonary hypertension in a portuguese population
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
HFWM: exploring biomarkers in chronic thromboembolic pulmonary hypertension (CTEPH): prognostic significance, and post-PEA dynamics analysis
Doctor A. Cuomo (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in valvular and pulmonary 4

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Associations of different definitions of iron deficiency with cardiac structure and function, congestion, exercise capacity and prognosis in heart failure
thumbnail
Congress Presentation
Iron deficiency in heart failure: comparison of esc criteria with alternative definitions
thumbnail
Congress Presentation
The effect of changes in ferritin levels on NTpro-BNP levels in the presence or absence of anemia in heart failure patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources